David A. Siegel Gilead Sciences, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 6,255,700 shares of GILD stock, worth $556 Million. This represents 0.98% of its overall portfolio holdings.

Number of Shares

6,255,700

Previous 5,079,600 23.15%

Holding current value

$556 Million

Previous $372 Million 15.35%

% of portfolio

0.98%

Previous 0.88%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $74.3 Million - $85.7 Million	1,176,100 Added 23.15%	6,255,700 $429 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $280 Million - $341 Million	3,910,300 Added 334.41%	5,079,600 $372 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $186 Million - $211 Million	-2,542,500 Reduced 68.5%	1,169,300 $94.7 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $19.9 Million - $21.7 Million	-268,500 Reduced 6.75%	3,711,800 $278 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $95.5 Million - $109 Million	-1,256,100 Reduced 23.99%	3,980,300 $307 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $14.7 Million - $16.7 Million	189,900 Added 3.76%	5,236,400 $434 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $50.9 Million - $73 Million	-816,000 Reduced 13.92%	5,046,500 $433 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $20.5 Million - $23.4 Million	344,800 Added 6.25%	5,862,500 $362 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $53 Million - $59.7 Million	918,800 Added 19.98%	5,517,700 $341 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $66.9 Million - $83.9 Million	1,155,800 Added 33.57%	4,598,900 $273 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $83.3 Million - $94.6 Million	-1,284,000 Reduced 27.16%	3,443,100 $250 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $318 Million - $344 Million	4,704,199 Added 20541.46%	4,727,100 $330 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $1.45 Million - $1.59 Million	22,901 New	22,901 $1.58 Million
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $328,570 - $374,390	-5,800 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$62.1 - $78.08 $7.48 Million - $9.41 Million	-120,470 Reduced 95.41%	5,800 $367,000
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $2.18 Million - $2.53 Million	-30,069 Reduced 19.23%	126,270 $9.72 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $191 Million - $245 Million	-3,056,101 Reduced 95.13%	156,339 $11.7 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $91.9 Million - $101 Million	-1,491,900 Reduced 31.71%	3,212,440 $209 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $33.2 Million - $36.7 Million	-531,300 Reduced 10.15%	4,704,340 $298 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $82.2 Million - $92.2 Million	1,328,600 Added 34.01%	5,235,640 $354 Million
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $175 Million - $196 Million	2,802,200 Added 253.63%	3,907,040 $254 Million
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $62.4 Million - $81.5 Million	1,031,502 Added 1406.5%	1,104,840 $69.1 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $1.25 Million - $1.39 Million	-17,600 Reduced 19.35%	73,338 $5.66 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $3.86 Million - $4.5 Million	-59,499 Reduced 39.55%	90,938 $6.44 Million
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $43.6 Million - $53.1 Million	-598,145 Reduced 79.9%	150,437 $11.3 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $182 Million - $214 Million	-2,558,687 Reduced 77.37%	748,582 $53.6 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $238 Million - $283 Million	3,307,269	3,307,269 $268 Million

Others Institutions Holding GILD

# of Institutions

1,895

Shares Held

1.02B

Call Options Held

12M

Put Options Held

9.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account